Phase 2 trial of Iberdomide in systemic lupus erythematosus.

Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Mixed Results for Oral Lupus Drug in Phase II— Mid-stage study offers hope but also reason for caution – MedPage Today (free registration required)

Commentary on Twitter

In patients with systemic lupus erythematosus, iberdomide at the highest dose, but not at lower doses, was superior to placebo with respect to the primary end point of an SRI-4 response at 24 weeks. https://t.co/rie3SRhoew pic.twitter.com/wRre5Gp1xB

— NEJM (@NEJM) March 17, 2022